By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals' dominance in the GLP-1 ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...

Merck announces a $2.0 billion agreement with Hansoh Pharma. The deal gives it rights to Hansoh's experimental weight-loss ...

But in an increasingly competitive market for weight loss drugs, these are not the only options for people looking to lose ...

Pennsylvania's Medicaid spending per enrollee on Wegovy, Zepbound and other anti-obesity drugs was third-highest in the ...

The woman was accused of selling counterfeit versions of popular weight loss drugs, including Ozempic and Wegovy. Experts say ...

GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

Health-care companies fell amid concerns about regulation from the Trump administration. A retreat for UnitedHealth Group continued after President-elect Donald Trump vowed to root "middle men" out of ...

Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...

Ratings for the No. 2 and No. 3 cable news networks have plummeted since Donald Trump's victory, while Fox News remains the leader. These companies largely earn their competitive advantage from ...

Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...